John L Lamattina insider trades: Ligand Pharmaceuticals (LGND) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
and 1 more company
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | LGND | ↓ Sell | 4,591 | $250.88 | $1.2M | Direct | Jun 12, 2026 (2d) |
| Mar 6, 2026 | LGND | ↓ Sell | 2,161 | $200.76 | $434K | Direct | Mar 31, 2026 (25d) |
| Nov 7, 2025 | LGND | ↓ Sell | 4,179 | $205.45 | $859K | Direct | Nov 12, 2025 (5d) |
| Nov 27, 2024 | LGND | ↓ Sell | 2,406 | $123.65 | $298K | Direct | Dec 2, 2024 (5d) |
| Nov 16, 2021 | LGND | ↓ Sell | 4,835 | $161.86 | $783K | Direct | Nov 17, 2021 (1d) |
| May 24, 2021 | IMNM | ↑ Buy | 5,440 | $18.57 | $101K | Direct | May 26, 2021 (2d) |
| Sep 4, 2018 | LGND | ↓ Sell10b5-1 | 3,335 | $254.96 | $850K | Direct | Sep 5, 2018 (1d) |
| Jun 4, 2018 | LGND | ↓ Sell10b5-1 | 4,000 | $194.51 | $778K | Direct | Jun 4, 2018 (0d) |
| Mar 5, 2018 | LGND | ↓ Sell10b5-1 | 3,335 | $160.90 | $537K | Direct | Mar 6, 2018 (1d) |
| Nov 17, 2017 | LGND | ↓ Sell | 4,000 | $139.79 | $559K | Direct | Nov 17, 2017 (0d) |
| Mar 18, 2014 | LGND | ↓ Sell | 5,000 | $78.83 | $394K | Direct | Mar 20, 2014 (2d) |
| Mar 11, 2011 | LGND | ↑ Buy | 10,000 | $9.80 | $98K | Direct | Mar 14, 2011 (3d) |
| Mar 13, 2009 | HGSI | ↑ Buy | 10,000 | $0.72 | $7K | Direct | Mar 16, 2009 (3d) |
| Nov 12, 2008 | HGSI | ↑ Buy | 20,000 | $2.19 | $44K | Direct | Nov 13, 2008 (1d) |
| Jun 15, 2007 | PFE | ↓ Sell | 36,066 | $26.48 | $955K | Direct | Jun 18, 2007 (3d) |
| Feb 7, 2007 | PFE | ↓ Sell | 13,800 | $26.54 | $366K | Direct | Feb 8, 2007 (1d) |
| May 6, 2005 | PFE | ↓ Sell | 39,789 | $27.81 | $1.1M | Direct | May 10, 2005 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LGND insiders
Open-market trades in the last 12 months
About John L Lamattina's insider trades
John L Lamattina is a director at Ligand Pharmaceuticals (LGND). Since May 6, 2005, John has reported 4 open-market purchases worth $250K and 13 sales worth $9.1M on SEC Form 4. In the last 12 months: 3 sales ($2.4M).
3 sales (24% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (102 filings), option exercises (12 filings), shares withheld for taxes (6 filings), gifts (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.